Literature DB >> 25786514

HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease.

R Rajbhandari1, C J Danford, R T Chung, A N Ananthakrishnan.   

Abstract

BACKGROUND: Little is known about outcomes of Hepatitis B virus (HBV)-related hospitalisations. AIM: To compare the characteristics and outcomes of hospitalised HBV patients to those with Hepatitis C virus (HCV) infection and alcoholic liver disease (ALD), and to examine variables associated with poor outcomes.
METHODS: Using the 2011 US Nationwide Inpatient Sample, we identified hospitalised patients with HBV, HCV or ALD-related admissions using ICD-9-CM codes. We compared liver-related complications between the three groups. Multivariable regression was performed to identify factors associated with in-hospital mortality and length of stay.
RESULTS: A total of 22 843 HBV, 203 300 HCV and 244 383 ALD-related discharges were included. Cirrhosis was noted less commonly in those with HBV (69.1%) compared to HCV (83.9%) or ALD (80.9%) (P < 0.001). In contrast, hepatocellular cancer and acute liver failure were more common with HBV (16.5% and 5.2%) compared to HCV (10.4% and 2.8%) or ALD (2.5% and 4.9%) respectively (P < 0.0001). On multivariable analysis, adjusting for demographics, liver and nonliver comorbidity, HBV infection was associated with higher mortality compared to HCV infection [Odds ratio (OR) 1.21, 95% CI: 1.04-1.39) or ALD (OR: 1.21, 95% CI: 1.05-1.40). Length of hospital stay was greater with HBV compared to HCV (+0.54 days) or ALD (+0.36 days). Among those with HBV, significant factors associated with mortality included renal failure, hepatocellular cancer, respiratory failure, ascites, coagulopathy and acute liver failure.
CONCLUSION: Patients hospitalised with HBV infection represent a particularly high-risk group with poor in-hospital outcomes and increased mortality compared to HCV infection or alcoholic liver disease.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 25786514     DOI: 10.1111/apt.13162

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection.

Authors:  L H Nguyen; J Hoang; N H Nguyen; V D Vu; C Wang; H N Trinh; J Li; J Q Zhang; M H Nguyen
Journal:  Aliment Pharmacol Ther       Date:  2016-07-01       Impact factor: 8.171

2.  In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.

Authors:  Lung-Yi Mak; Sze-Hang Liu; Desmond Yat-Hin Yap; Wai-Kay Seto; Danny Ka-Ho Wong; James Fung; Tak-Mao Chan; Ching-Lung Lai; Man-Fung Yuen
Journal:  Dig Dis Sci       Date:  2019-07-06       Impact factor: 3.199

3.  Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.

Authors:  Haesuk Park; Donghak Jeong; Pauline Nguyen; Linda Henry; Joseph Hoang; Yoona Kim; Edward Sheen; Mindie H Nguyen
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

4.  Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis.

Authors:  Adeyinka Charles Adejumo; Oluwole Muyiwa Adegbala; Kelechi Lauretta Adejumo; Terence Ndonyi Bukong
Journal:  Can J Gastroenterol Hepatol       Date:  2018-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.